Compare McKesson Corporation (MCK) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs TORM plc — how do they compare? McKesson Corporation trades at $824.96 (market cap $97.35B), while TORM plc trades at $29.83 (market cap $2.99B). The key difference: McKesson Corporation is far larger — about 32.6× TORM plc's market cap, and TORM plc pays the higher dividend (9.62%). Which is the better fit depends on your goals.
| MCK | TRMD | |
|---|---|---|
Market Cap | $97.35B | $2.99B |
Sector | Health | Technology |
52-Week High | $995.69 | $34.87 |
52-Week Low | $659.01 | $17.50 |
Enterprise Value | $101.98B | $3.88B |
Dividend Yield | 0.39% | 9.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
TRMD trades at $29.08, up 2.21% today, with a neutral technical signal. The company reported strong profitability with a 24.41% net income margin and a low P/E of 8.34. Recent earnings showed a Q1 2026 miss but Q4 2025 beat, with Q2 2026 results pending. Cash flow from operations remains robust at $552 million in 2026, though net cash flow is negative. A $0.70 dividend for H1 2026 is scheduled, reflecting shareholder returns.
Outlook is positive due to strong fundamentals and 100% buy ratings from analysts, but risks include earnings volatility and negative net cash flow. The stock offers value with attractive valuation metrics and dividend yield, though investors should monitor Q2 earnings and cash flow trends for sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
